A Novel Selective ERK1/2 Inhibitor, Laxiflorin B, Targets EGFR Mutation Subtypes in Non-small-cell Lung Cancer
C. Chiang, M. Zhang, J. Huang, J. Zeng, C. Chen, D. Pan, H. Yang, M. Yang, Q. Han, W. Zou, T. Xiao, Y. Zou, F. Yin, Z. Li, L. Zhu, D. Zheng
This study identifies Laxiflorin B, a novel ERK1/2 inhibitor, showing efficacy against EGFR mutant NSCLC through apoptosis induction and suppression of AREG/EREG.
bioRxiv · Jun 27, 2022Pharmacology & Toxicology